Where Will Viking Therapeutics Be in 5 Years?

If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (NASDAQ: VKTX). Although the business isn't generating any revenue yet, there's loads of opportunity for the company in the long run.

Below, I'll look at what the future may hold for Viking and whether it could be a good stock to buy and hold for at least the next five years.

The big question surrounding Viking Therapeutics today centers around its promising glucagon-like peptide 1 (GLP-1) drug, VK2735. Within the next five years, investors will likely have learned the fate of the drug and whether it obtains approval from regulators or not.

Source Fool.com